Recardio Inc.
Recardio is a late clinical-stage life science company specializing in regenerative therapies for cardiovascular and other diseases. Located in San Francisco, California, with operations in the USA and Europe, the company focuses on activating the body's own regenerative capacity to heal cardiac tissue after injury, with its lead drug candidate being dutogliptin, a DPP-IV inhibitor. Recardio aims to revolutionize cardiovascular care through innovative therapies and cutting-edge technology initiatives, including advanced diagnostics and digital health solutions. The company collaborates with pharmaceutical leaders and offers partnership opportunities to advance its multiple product leads in cardiology.
Industries
Nr. of Employees
small (1-50)
Recardio Inc.
Products
Clinical-stage DPP‑IV inhibitor therapeutic (lead candidate)
A clinical-stage small-molecule DPP‑IV inhibitor designed to activate chemokine signaling pathways (for example SDF-1) with the aim of promoting cardiac tissue repair following injury; advanced to global pivotal Phase 3 evaluation.
Clinical-stage DPP‑IV inhibitor therapeutic (lead candidate)
A clinical-stage small-molecule DPP‑IV inhibitor designed to activate chemokine signaling pathways (for example SDF-1) with the aim of promoting cardiac tissue repair following injury; advanced to global pivotal Phase 3 evaluation.
Services
Partnering and licensing for therapeutic assets
Negotiation and collaboration services for co-development, licensing and out-licensing of cardiovascular therapeutic and technology assets.
Partnering and licensing for therapeutic assets
Negotiation and collaboration services for co-development, licensing and out-licensing of cardiovascular therapeutic and technology assets.
Expertise Areas
- Regenerative cardiac medicine
- Cardiovascular drug development
- Clinical trial management and execution (Phase 3)
- Preclinical development and translational research
Key Technologies
- DPP‑IV inhibition (small molecules)
- Chemokine modulation (SDF-1 signaling)
- Translational biomarker strategies
- Advanced cardiovascular diagnostics